Topic overview

Start with the big picture

RA treatment seeks to reach remission or low disease activity, with therapy adjusted toward that target. NSAIDs and COX-2 inhibitors can relieve symptoms but do not modify disease progression, while glucocorticoids may serve as a time-limited bridge. Conventional synthetic DMARDs (csDMARDs), including methotrexate, form a central part of disease-modifying treatment. If response is inadequate, biologic or targeted synthetic DMARDs may be considered; these options have distinct screening, monitoring, and safety requirements. The lesson also addresses treatment adjustment, patient education, and practical precautions, including vaccination and important medicine interactions. Together, these principles frame RA care as an ongoing balance of disease control, medication safety, and follow-up.